| Literature DB >> 35415680 |
Rona Karmela D Bravo1, Mark Rickard N Angelia1, Lawrence Yves C Uy1,2,3,4, Roberta N Garcia5, Mary Ann O Torio1.
Abstract
Previous studies in pigeon pea showed health benefits but very few explored peptide bioactivities. This study examined antimicrobial, antioxidant, and antihypertensive activities of peptides in purified and proteolyzed major globulin fraction, cajanin, of pigeon pea (Cajanus cajan) seeds. In-silico analysis showed 41 antihypertensive and nine antioxidant peptides but zero antibacterial peptides from cajanin sequence. The Pepsin-Chymotrypsin-Trypsin (PCT) protein digest has no antibacterial activity against Escherichia coli, Candida albicans, and Staphylococcus aureus but has high % ACE inhibition (87.50%). Two HPLC fractions showed low IC50 values (HPLC Fraction 1: 0.00535 mg/ml; HPLC Fraction 2: 0.00432 mg/ml), comparable to Captopril (0.00379 mg/ml). This fractions also showed H2O2 scavenging activity (HPLC Fraction 1: 1.47%; HPLC Fraction 2: 1.51%) and Total Antioxidative Capacity of 0.00088 mg/mL (HPLC Fraction1) and 0.00110 mg/mL (HPLC Fraction 2) ascorbic acid equivalent. Results from this study serve as reference for further investigations of novel pharmaceutical agents that can be derived from legumes.Entities:
Keywords: Antibacterial; Antihypertensive; Antioxidative; Bioactive peptides; Cajanus cajan; Globulin; Pigeon pea
Year: 2021 PMID: 35415680 PMCID: PMC8991556 DOI: 10.1016/j.fochms.2021.100062
Source DB: PubMed Journal: Food Chem (Oxf) ISSN: 2666-5662
Bioactive peptides that exhibit antihypertensive and antioxidative activities that are found in the sequence of cajanin from Pigeon peas.
| Peptide sequence | Location | Activity |
|---|---|---|
| TK | [3–4] | ACE inhibition |
| VF | [9–10] | ACE inhibition |
| VP | [17–18] | ACE inhibition |
| KYL | [19–21] | ACE inhibition |
| IY | [26–27] | ACE inhibition |
| EYK | [31–33] | ACE inhibition |
| KPR | [35–37] | ACE inhibition |
| LFLPQY | [39–44] | ACE inhibition |
| DA | [46–47] | ACE inhibition |
| ILVV | [50–53] | ACE inhibition |
| SGKA | [55–58] | ACE inhibition |
| SF | [70–71, 115–116, 152–153, 231–231] | ACE inhibition |
| LVRGDT | [55–58] | ACE inhibition |
| KL | [80–81] | ACE inhibition |
| AGTIAYLA | [83–90] | ACE inhibition |
| VLDL | [100–103] | ACE inhibition |
| YNKPGQLQS | [107–115] | ACE inhibition |
| SGTQ | [119–122] | ACE inhibition |
| SGF | [129–131] | ACE inhibition |
| EAGCF | [137–141] | ACE inhibition |
| GD | [75–76, 147–148, 240–241, 280–281] | ACE inhibition |
| KGSFR | [150–154] | ACE inhibition |
| TGTRA | [156–160] | ACE inhibition |
| TQK | [162–164] | ACE inhibition |
| RR | [169–170] | ACE inhibition |
| EI | [172–173] | ACE inhibition |
| IE | [185–186] | ACE inhibition |
| PVPK | [194–197] | ACE inhibition |
| SGT | [119–121, 203–205] | ACE inhibition |
| TGS | [216–218] | ACE inhibition |
| RF | [227–228] | ACE inhibition |
| LYIGD | [237–241] | ACE inhibition |
| GQ | [111–112,246–247] | ACE inhibition |
| YKE | [256–258] | ACE inhibition |
| VR | [74–75, 273–274, 317–318] | ACE inhibition |
| KLPGDVFVIPAGHP | [276–290] | ACE inhibition |
| AI | [292–293] | ACE inhibition |
| LN | [299–300] | ACE inhibition |
| IGFGILA | [302–308] | ACE inhibition |
| NY | [310–311] | ACE inhibition |
| SLVR | [315–318] | ACE inhibition |
| LK | [21–22, 63–64] | Antioxidation |
| IY | [26–27,213–214] | Antioxidation |
| KP | [35–36,109–110] | Antioxidation |
| IKLPAG | [79–84] | Antioxidation |
| AY | [87–88] | Antioxidation |
| KD | [167–168] | Antioxidation |
| EL | [187–188, 243–244] | Antioxidation |
| IY | [26–27,213–214] | Antioxidation |
| PAG | [82–84,286–288] | Antioxidation |
Source: Minkiewicz P., Dziuba J., Iwaniak A., Dziuba M., Darewicz M., BIOPEP database and other programs for processing bioactive peptide sequences. Journal of AOAC International, 91, 2008, 965–980.
Fig. 1SDS-PAGE profile of the protein digests using different enzymes and enzyme combinations. Lane 1: Protein MW standard: 10–225 kDa; Lane 2: Undigested purified protein; Lanes 3 to 9: 0, 3, 5, 10, 20, 60 mins, 24 h-digests, respectively.
Fig. 2The elution profiles obtained from each trial (A-Trial 1, B-Trial2, C-Trial3) after subjecting the three-enzyme digest (PCT) in High Performance Liquid Chromatography. Eluents obtained at an average elution time of 6 min.
Fig. 3Antioxidant activity of PCT digest and fractions; A·H2O2-scavenging activity of PCT digest and fractions compared to ascorbic acid; B. Total antioxidant activity of PCT digest and fractions expressed in mg/ml ascorbic acid equivalents.
Fig. 4ACE inhibition activity of protein digests and fractions against positive control (Captopril): A. ACE inhibition activity (%) of different protein digests; B. IC50 values of the protein digests and the HPLC fractions.
The amino acid composition and the possible amino acid sequence of the two HPLC fractions.
| Fraction | Possible Amino Acid Sequence | Reference |
|---|---|---|
| Fraction 1 | RA | |
| RR | ||
| DA | ||
| Fraction 2 | LK | |
| KL | ||
| RA | ||
| RR | ||
| DA |